Avasimibe

CAT: 804-HY-13215-01Size: 5 mgDry Ice: NoHazardous: No
5 mgSelected
AVAILABILITY
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Product image 1
1 / 1
Description
Avasimibe (CI-1011; PD-148515) is an orally active acyl coenzyme A-cholesterol acyltransferase (ACAT; also called SOAT) ) inhibitor with IC50s of 24 and 9.2 µM for ACAT1 and ACAT2, respectively[1]. Avasimibe can be used for the research of prostate cancer[2].
CAS Number
[166518-60-1]
Product Name Alternative
CI-1011; PD-148515
UNSPSC
12352005
Hazard Statement
H302, H315, H319, H335
Target
Acyltransferase
Type
Reference compound
Related Pathways
Metabolic Enzyme/Protease
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/Avasimibe.html
Concentration
10mM
Purity
99.85
Solubility
DMSO : 100 mg/mL (ultrasonic)
Smiles
O=C(NS(=O)(OC1=C(C(C)C)C=CC=C1C(C)C)=O)CC2=C(C(C)C)C=C(C(C)C)C=C2C(C)C
Molecular Formula
C29H43NO4S
Molecular Weight
501.72
Precautions
H302, H315, H319, H335
References & Citations
[1]Taichi Ohshiro, et al. Pyripyropene A, an acyl-coenzyme A:cholesterol acyltransferase 2-selective inhibitor, attenuates hypercholesterolemia and atherosclerosis in murine models of hyperlipidemia. Arterioscler Thromb Vasc Biol. 2011 May;31 (5) :1108-15.|[2]Kangping Xiong, et al. The cholesterol esterification inhibitor avasimibe suppresses tumour proliferation and metastasis via the E2F-1 signalling pathway in prostate cancer.Cancer Cell Int. 2021 Aug 30;21 (1) :461.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
Phase 3
Isoform
ACAT1; ACAT2

Related Products

CatalogName